FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average burden										
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person*					2. Issuer Name <b>and</b> Ticker or Trading Symbol MERRIMACK PHARMACEUTICALS INC									5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
Mulroy Robert J.						MERRIMACK PHARMACEO FICALS INC   MACK								X	Director		10% Owner		vner	
(Last)	(E	First)	(Middle)		- <u>L</u>	1,11,10								_ x	Officer (	(give title		Other (s	specify	
C/O MERRIMACK PHARMACEUTICALS, INC.						3. Date of Earliest Transaction (Month/Day/Year)									President and CEO					
ONE KENDALL SQUARE, SUITE B7201						08/21/2014														
						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Inc	6. Individual or Joint/Group Filing (Check Applicable					
(Street)														Line)	Form fil	ad by One	Dono	ting Doroor		
CAMBRIDGE MA 02139														^	Form filed by One Reporting Person  Form filed by More than One Reporting					
				-										Person	cu by Wor	C tritari	One repor	ung		
(City)	(S	State)	(Zip)																	
		Та	ble I - Noi	n-Der	ivativ	ve Se	curi	ities Ac	quire	I, Dis	posed	of, or B	enef	icially	Owned					
Date				nsactio		2A. Deemed Execution Date, if any						ities Acquired (A) or d Of (D) (Instr. 3, 4 and			5. Amount of Securities Beneficially		Direct	7. Nature of Indirect Beneficial		
(inc					Zuj.	(Month/Day/Year)				· (ot.					Owned F	ollowing		str. 4)	Ownership (Instr. 4)	
								Cod	e v	Amount	Amount (A) or (D)		Price	Transaction(s) (Instr. 3 and 4)				` ′		
Common Stock 08/21					21/20	/2014		М	Т	280,1	280,168 A		\$1.25	1,220	226,237		D			
			Table II -	Deriv	ative	Sec	uriti	es Aca	uired.	Disc	osed of	. or Be	nefic	ially C	wned					
											convert									
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Da if any (Month/Day/\	Co	Transa Code (	ransaction ode (Instr.		Derivative		6. Date Exercisable Expiration Date (Month/Day/Year)		of Securities		urity	8. Price of Derivative Security (Instr. 5)	9. Numbe derivative Securities Beneficia Owned Following Reported Transacti	e s illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)	
													An	ount		(Instr. 4)	On(3)			
					Code	v	(A)	(D)	Date Exercis		Expiration Date	Title	Nu	mber Shares						
Stock Option (right to buy)	\$1.25	08/21/2014			M			141,952	(1)		08/30/2014	Common Stock	14	1,952	\$0	0		D		
Stock Option (right to	\$1.25	08/21/2014			М			138,216	(1)		08/30/2014	Common Stock	13	8,216	\$0	19,83	2	D		

## **Explanation of Responses:**

1. This option is fully vested.

/s/ Jeffrey A. Munsie, attorney-

\*\* Signature of Reporting Person

in-fact

08/25/2014

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.